Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300. The lead Taiwan site is now open to accrual and actively screening patients, with Lantern anticipating IRB approval at two additional sites during the fourth quarter. In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation.
Part 2 of the HARMONIC trial will enroll patients with the L858R mutation who have progressed after tyrosine kinase inhibitor treatment. The amended protocol allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously. This expansion is based on preliminary data showing a median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. The company emphasized that these findings are preliminary, exploratory, and based on small patient numbers.
The approvals in Taiwan and the amended protocol in the U.S. are significant steps for Lantern Pharma, as they broaden the geographic reach of the HARMONIC trial and potentially enhance the treatment regimen for a specific, biomarker-defined patient population. The L858R mutation is one of the most common EGFR mutations in non-small cell lung cancer, and patients who progress after tyrosine kinase inhibitors have limited options. By extending LP-300 treatment to eight cycles, Lantern hopes to improve outcomes for these patients, though further data are needed to confirm any benefit.
Lantern Pharma leverages its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For more details on the trial and the company, see the full press release at https://ibn.fm/CqeDR.
Investors and industry observers can follow the latest updates on Lantern Pharma in the company’s newsroom at https://ibn.fm/LTRN. The news was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions through InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement to ensure maximum impact.
For Lantern Pharma, the Taiwan approvals represent a critical milestone in advancing a biomarker-driven therapy that could address an unmet need in lung cancer. If the extended treatment regimen demonstrates improved efficacy in the ongoing trial, it could influence future clinical practice and regulatory submissions. However, the preliminary nature of the data means that definitive conclusions await the completion of Part 2 and further analysis.
